Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018–2022 Global Surveillance
Based on in vitro data, IMI/REL represents a good therapeutic option for most hospitalized pediatric patients infected with common Gram-negative pathogens.
Authors
- Fakhar Siddiqui
- C Andrew DeRyke (ORCID: https://orcid.org/0000-0001-5942-9707)
- Katherine Young (ORCID: https://orcid.org/0000-0002-1490-5455)
- Mark G. Wise (ORCID: https://orcid.org/0000-0001-7356-1851)
- Mary Motyl (ORCID: https://orcid.org/0000-0003-3142-8475)
- Karri A. Bauer
- Daniel F. Sahm
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- American Veterinary Medical Association (US)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/jpids/piae134
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59